Already a Vigil Neuroscience investor, Sanofi has agreed to buy the rest of the biotech’s shares for $8 apiece, representing a total deal value of $470 million.

The Herpes simplex virus hides in plain sight. For most, it’s a fleeting nuisance — a tingling lip, a blister, a cold sore.

Vigil Neuroscience shares jumped nearly 250% Thursday after the Alzheimer's disease drug developer reached a deal to be ...

Could cold sores be linked to an increased risk of developing dementia? Could cold sore treatment be used to treat ...

Real Housewives of Atlanta’ alum Kandi Burrus revealed that her Aunt Bertha Jones was diagnosed with Alzheimer’s disease and it hasn’t been easy for her family to manage.

Dementia affects millions globally, impacting memory, reasoning, and everyday activities. As the population ages, understanding and addressing cognitive decline becomes increasingly critical.

Alzheimer’s researcher Donald Weaver tells The Conversation Weekly podcast what he’s learnt during more than 30 years of studying the disease.

Sanofi’s 11 months watching over Vigil Neuroscience have led to a $470 million buyout. | Sanofi’s 11 months watching over ...

Alzheimer’s is a complex disease caused by many interacting factors. It’s possible the herpes virus could play a small role – ...

New US dementia cases decreased between 2015 and 2021, but the number of people living with the disease continued to increase.

Sanofi said it entered an agreement to acquire Vigil Neuroscience for approximately $470 million, a deal that adds a new investigational treatment for Alzheimer's disease to the French pharmaceutical ...

The first Alzheimer's blood test cleared by the Food And Drug Administration is poised to change the way doctors diagnose and ...